BioWorld

Nov. 14, 2006

Illumina Taking Over Solexa In $660M Stock-Swap Deal

Illumina Inc.'s plan to take over Solexa Inc. in a $600 million stock swap recalls the buyout of CyVera Corp. early last year, which provided Illumina an entry into the diagnostics field. (BioWorld Today) Read More

Favrille Falls On Interim Analysis Of Pivotal FavId Study In NHL

Research in Gene Expression Leads To Findings In Epilepsy

HDL-Focused Cerenis Raises $53.5M In Series B Financing

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...